Back to Search

A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors

  • Protocol Number: 202205147
  • Principal Investigator: Oppelt, Peter
  • Cancer Types: Early Phase, GU: Bladder, Kidney, Prostate, Testicular, Head & Neck, Lung, Melanoma & Skin, Sarcoma

For more information on this trial, contact us here:

[email protected]

Brief Summary

Protocol Interventions